Contribute
España
Italia
대한민국
日本
Français

Benzinga

Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
767.290.02%
QQQ
716.960.08%
BTC/USD
64530.190.0778%
DIA
532.850.01%
GLD
398.160.1%
TLT
81.680.02%
Updated: Aug 18, 2026

Analyst Stock Ratings

Analyst downgrades are often a bearish signal for a stock. When an analyst downgrades a stock it means the stock rating is lower than it previously was and the analyst likely does not recommend people buy the stock.

Buy NowGet Alert
08/18/2026WEAVBuy Now
Weave Communications
$7.291.53%Piper Sandler$8 → $7.4DowngradeOverweight → NeutralGet Alert
08/18/2026YSSBuy Now
York Space Systems
$10.5028.57%Canaccord Genuity$36 → $13.5DowngradeBuy → HoldGet Alert

Recent Analyst Stock Rating Downgrades News

PRO
Watching Carvana; Hunterbrook Media Issues Report Titled "Walter and TWG Global Likely Can’t Use CVNA for Liquidity. Citi Already Secured It."; States Hunterbrook Capital Is Long $CVNA
https://hntrbrk.com/breaking-news/carvana
PRO
Watching BRP; Shares Move Higher, Bloomberg Reports TD Cowen Upgrades Stock To Buy On SxS Momentum And Easing Tariff Concerns
AI Agents Are Creating a New Cybersecurity Boom: 3 Stocks to Watch
AI Agents Are Creating a New Cybersecurity Boom: 3 Stocks to Watch
AI agents are creating new security risks. Bank of America analyst Tal Liani sees higher valuations for cybersecurity stocks.
PRO
Piper Sandler Downgrades Weave Communications to Neutral, Lowers Price Target to $7.4
Piper Sandler analyst Hannah Rudoff downgrades Weave Communications (NYSE:WEAV) from Overweight to Neutral and lowers the price target from $8 to $7.4.
PRO
HC Wainwright & Co. Maintains Buy on Intensity Therapeutics, Raises Price Target to $7
HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Intensity Therapeutics (NASDAQ:INTS) with a Buy and raises the price target from $5 to $7.
BioMarin Seeks to Strengthen Market Position in Rare Bone Disease Treatment
BioMarin Seeks to Strengthen Market Position in Rare Bone Disease Treatment
BioMarin Pharmaceutical agrees to acquire Alesta Therapeutics for $275 million upfront, securing ALE1 for rare bone disease treatment.
PRO
Truist Securities Maintains Buy on argenx, Raises Price Target to $1095
Truist Securities analyst Danielle Brill maintains argenx (NASDAQ:ARGX) with a Buy and raises the price target from $1030 to $1095.
Nvidia Stock Has 55% Upside, Analyst Says — Here’s What Investors Miss
Nvidia Stock Has 55% Upside, Analyst Says — Here’s What Investors Miss
Nvidia is committing billions to the AI ecosystem. Bank of America says the market may be underpricing the strategy, with 55% upside.
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free
Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved